MIEBO™ (perfluorohexyloctane ophthalmic solution): Bridging a Major Gap in the Rx Treatment of Evaporative Dry Eye Disease

This program will examine how excessive evaporation is a key cause of DED and how it may be addressed with Miebo™ (perfluorohexyloctane ophthalmic solution).

Join the experts for:

A brief overview of the importance of evaporation in dry eye disease
Introduction to Miebo™ – overview of key features and mechanism of action
Information on how Miebo™ is different and uniquely designed to mimic a key function of natural meibum by reducing tear evaporation
Review of pivotal efficacy and safety data
Case presentation(s) to identify appropriate evaporative dry eye disease patient profiles

INDICATION
MIEBO™ (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
Instruct patients to instill one drop of MIEBO into each eye four times daily
The safety and efficacy in pediatric patients below the age of 18 have not been established
The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for MIEBO here.